Search / 920 posts tagged prostate cancer

. LONDON, England (BBC News), October 7, 2008 Eating meat and dairy products may increase the risk of prostate cancer, research suggests. Such a diet raises levels of a hormone called Insulin-like Growth Factor-1 (IGF-1) which promotes cell growth.

Study used different scale of heaviness Saying that the British obesity problem is worse than thought, a researcher from the Mayo Clinic said three quarters of all British adults should be classified as overweight, about 10 percent more than currently fall into that category. Dr.

A new U.N. report asks if the harms caused by biofuels outweigh their benefits. (AFP) A new study by Oxford University links meat and dairy consumption to an increased risk of prostate cancer. (BBC News) 'Tis the season: Yesterday it was Michelin. Today Zagat reveals its annual restaurant guide for New York City.

A private insurer is calling for CMS to issue a national non-coverage decision for proton therapy in treating prostate cancer, claiming Medicare payments will encourage rapid spread of the costly technology before there is enough clinical evidence to deem the treatment reasonable and necessary.

Meat 'ups prostate cancer risk' BBC News | Health | World Edition Tue, 10/07/2008 - 06:16 Eating meat and dairy products may increase the risk of developing prostate cancer, research suggests.

Toronto, Oct 7 (IANS) Prostate cancer patients who are overweight and have elevated insulin levels are at much higher risk of dying than other patients, a new Canadian study says.As part of their study, researchers at Montreal-based McGill University, in collaboration with Harvard University, analysed

Breaking Down Dendreon’s Move (DNDN) October 6, 2008 · Filed Under Cancer, dendreon · Comments Off Dendreon Corp. (NASDAQ: DNDN) is one biotech stock where traders and investors alike also join groups of patients in their march toward to the company.  The stock was an incredible performer today, and one which makes you wonder how well it would have done had the stock market not been so ugly.

Dendreon (DNDN) Prostate Cancer Treatment PROVENGE Improves Survival Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also

Amid the stock sell-off, a bright spot appears and, of all things, it turns out to be Dendreon, the controversial and much-maligned little company that continues to press ahead with its Provenge prostate cancer vaccine.

Biotech, cancer, Dendreon Luke Timmerman wrote: Dendreon’s stock rocketed up 55 percent this morning on good news for its Provenge treatment for prostate cancer. The Seattle biotech company (NASDAQ: DNDN) said today that an independent board of trial monitors reported that patients on Provenge have